AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

Dr. Carl Dieffenbach: IAS Conference Highlights HIV Treatment Advances – Day 4

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), Kuala Lumpur, Malaysia.

Today was the final day of the 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lampur, Malaysia. This week, we’ve asked Dr. Carl Dieffenbach from NIH/NIAID, to share daily dispatches from this important scientific conference via Skype. As Dr. Dieffenbach related, research related to significant HIV treatment advances has been a major…

Dr. Carl Dieffenbach: 7th International AIDS Society (IAS) Conference Addresses Social Determinants of Health – Day 3

IAS 2013

Yesterday, July 2, was the second full day of the 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lampur, Malaysia. This week, we’ve asked Dr. Carl Dieffenbach from NIH/NIAID to share daily highlights from this important scientific conference via Skype. As Dr. Dieffenbach shared, researchers at the conference discussed the social determinants of…

Dr. Carl Dieffenbach: 7th International AIDS Society (IAS) Conference Highlights Value of Treatment Cascade – Day 2

IAS Day 2

Yesterday, July 1, was the first full day of the 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lampur, Malaysia—the world’s largest scientific conference on HIV/AIDS. This week, we’ve asked Dr. Carl Dieffenbach from NIH/NIAID, to share daily highlights from the conference via Skype. Dr. Dieffenbach relayed that one of the themes…

Highlights from the 7th International AIDS Society (IAS) Conference Opening Session

International AIDS Society Day 1

June 30, 2013, was the opening plenary of the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lampur, Malaysia. We asked Dr. Carl Dieffenbach, Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), to share highlights from the conference via Skype. Please…

FDA approves first genotyping test for patients with hepatitis C virus

FDA

The U.S. Food and Drug Administration today approved a test that identifies the genotype of hepatitis C virus (HCV) that a patient is carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an infected patient’s blood plasma or serum, will aid health…

Implementing HIV Prevention Methods on the Local Level: Mario Perez Discusses Use of PrEP in Los Angeles County

Mario Perez

As outlined in the National HIV/AIDS Strategy, one of the key steps to successfully reducing the number of new HIV infections in the U.S. is expanding targeted HIV prevention efforts using a combination of effective, evidence-based approaches. Recently, we had the opportunity to speak with Mario Pérez, Director of the Division of HIV and STD…

CDC Recommends PrEP for Injection Drug Users

Jonathan Mermin

The Center for Disease Control and Prevention (CDC) today published in the weekly Morbidity and Mortality Weekly Report interim guidance for the use of Preexposure Prophylaxis (PrEP) for the prevention of HIV infection among Injecting Drug Users (IDUs). Results from a randomized controlled trial in Bangkok, Thailand, of a daily oral dose of 300 mg…

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

CDC Logo

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…